News

Eylea Approved for Diabetic Retinopathy Treatment

Regeneron Pharmaceuticals, Inc. has announced FDA approval of Eylea (aflibercept) injection to treat all stages of diabetic retinopathy. Eylea is already approved for treatment of three conditions: neovascular (wet) age-related macular degeneration, macular edema resulting from retinal vein occlusion, and diabetic macular edema.  This additional use of Eylea for diabetic retinopathy was approved based upon [Read More]

Need For Improvement in Hospital Care For Vision-Impaired Patients

Recent research spotlights a need to address certain risks and incapacities with which people with visual impairment are faced during hospital stays. Vision-impaired hospital patients have worse clinical outcomes, more readmissions, longer lengths of stay, and higher costs of care than non-vision-impaired patients, according to the authors. The article, published April 4, 2019 in JAMA [Read More]

A portable hand-held electronic reader for less than $200

Low vision presents many challenges in managing daily living activities, with one of the most important being spot reading. This includes reading labels, instructions, envelope addresses, checkbooks, receipts, menus, food containers, recipes, clocks, signs, written notes, currency values, and on and on. With loss of functional eyesight, such normally routine tasks require either accommodating, seeking [Read More]